Filing Flows › ANI Pharmaceuticals (ANIP) › Net income
ANI Pharmaceuticals (ANIP) net income by quarter
ANI Pharmaceuticals' net income was $35.1M in Q3 2026 (third quarter 2026), +42% from Q2 2026. Over the last 7 quarters it ranged from $8.5M (Q2 2025) to $35.1M (Q3 2026).
| Quarter | Net income | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $35.1M | +42% | +32% |
| Q2 2026 | $24.7M | -16% | +189% |
| Q1 2026 | $29.5M | +7% | +88% |
| Q4 2025 | $27.5M | +3% | — |
| Q3 2025 | $26.6M | +211% | — |
| Q2 2025 | $8.5M | -45% | — |
| Q1 2025 | $15.7M | — | — |
Q3 2026 at a glance
ANI Pharmaceuticals, Q3 2026: revenue $291M (+28% year over year), operating margin 18.0%, net earnings $35.1M, operating cash flow $83.8M. The chart follows the revenue to costs, profit and cash.
Questions
What is ANI Pharmaceuticals' net income?
ANI Pharmaceuticals' net income was $35.1M in Q3 2026 (third quarter 2026), +42% from Q2 2026.
How has ANI Pharmaceuticals' net income changed?
Over the last 7 quarters it ranged from $8.5M (Q2 2025) to $35.1M (Q3 2026).